NCT03347786

Verapamil for Neuroprotection in Stroke

Intraarterial Verapamil for Neuroprotection in Ischemic Stroke

• Status: Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Global Neurosciences Institute · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this research study is to test an experimental procedure called intra-arterial delivery of verapamil in patients diagnosed with acute ischemic stroke. This study investigates the safety of intra-arterial delivery of verapamil, a drug used to treat vasospasm (spasm of a blood vessel), and how it affects recovery from stroke. Recruitment is limited to patients that have received mechanical thrombectomy as standard of care.

Conditions

• Ischemic Stroke

Interventions

Type	Name	Description
DRUG	10 mg Intra-arterial Verapamil	Intra-arterial delivery of verapamil following mechanical thrombectomy procedure will be administered at a randomized dose of 10 mg or 20 mg to consenting patients.
DRUG	20 mg Intra-arterial Verapamil	Intra-arterial delivery of verapamil following mechanical thrombectomy procedure will be administered at a randomized dose of 10 mg or 20 mg to consenting patients.

Timeline

• Start date: 2017-04-20
• Primary completion: 2026-08-01
• Completion: 2026-12-01
• First posted: 2017-11-20
• Last updated: 2025-01-17

Locations

3 sites across 1 country: United States

Regulatory

• FDA-regulated drug study